Hjem
  • E-postEystein.Husebye@uib.no
  • Telefon+47 55 97 30 78
  • Besøksadresse
    Jonas Liesvei 91
    5021 Bergen
  • Postadresse
    Postboks 7804
    5020 Bergen

Addison's sykdom (binyrebarksvikt)

Autoimmune polyendokrine syndromer

Hypoparathyroidisme

Hormonsykdommer

Vitenskapelig artikkel
  • 2019. Identification and characterization of rare Toll-like receptor 3 variants in patients with autoimmune Addison’s disease. Journal of translational autoimmunity.
  • 2019. Coexistence of congenital adrenal hyperplasia and autoimmune Addison's disease. Frontiers in Endocrinology. 1-5.
  • 2018. The short cosyntropin test revisited: new normal reference range using LC-MS/MS. Journal of Clinical Endocrinology and Metabolism. 1696-1703.
  • 2018. Oral tongue malignancies in Autoimmune polyendocrine syndrome type 1. Frontiers in Endocrinology. 1-9.
  • 2018. Oral microbiota in autoimmune polyendocrine syndrome type 1. Journal of Oral Microbiology. 1-10.
  • 2018. Metabolic complications in adrenal insufficiency. Frontiers of Hormone Research. 104-113.
  • 2018. Is there a need for an emergency card in hypoparathyroidism? Journal of Internal Medicine. 1-7.
  • 2018. High-dose vitamin D in Addison's disease regulates T-cells and monocytes: A pilot trial. Nutrition - The International Journal of Applied and Basic Nutritional Sciences. 66-73.
  • 2018. HbA1c predicts long-term postoperative mortality in patients with unknown glycemic status at admission for vascular surgery: An exploratory study. Journal of Diabetes. 1-11.
  • 2018. Cytokine autoantibody screening in the Swedish Addison Registry identifies patients with undiagnosed APS1. Journal of Clinical Endocrinology and Metabolism. 179-186.
  • 2018. Clinical and immunological characteristics of diabetes mellitus in patients with autoimmune polyglandular syndrome type 1 in Russia. Sakharnyi Diabet. 48-57.
  • 2018. Cardiac magnetic resonance imaging of myocardial mass and fibrosis in primary aldosteronism. Endocrine Connections. 413-424.
  • 2018. Autoimmune Addison's disease – An update on pathogenesis. Annales d'Endocrinologie. 157-163.
  • 2018. Assay of steroids by liquid chromatography-tandem mass spectrometry in monitoring 21-hydroxylase deficiency. Endocrine Connections. 1542-1550.
  • 2018. Adrenal Venous Sampling for Assessment of Autonomous Cortisol Secretion. Journal of Clinical Endocrinology and Metabolism. 4553-4560.
  • 2018. A wide spectrum of autoimmune manifestations and other symptoms suggesting immune dysregulation in patients with cartilage-hair hypoplasia. Frontiers in Immunology.
  • 2018. 21-hydroxylase autoantibodies are more prevalent in Turner syndrome but without an association to the autoimmune polyendocrine syndrome type I. Clinical and Experimental Immunology. 1-5.
  • 2017. Expanding the Phenotypic and Genotypic Landscape of Autoimmune Polyendocrine Syndrome Type 1. Journal of Pediatric Endocrinology & Metabolism (JPEM). 3546-3556.
  • 2017. Clues for early detection of autoimmune Addison's disease - myths and realities. Journal of Internal Medicine. 190-199.
  • 2017. Clinical Characteristics and Long-Term Outcome of Primary Aldosteronism in a Norwegian Population. Hormone and Metabolic Research. 838-846.
  • 2017. Autoantibody repertoire in APECED patients targets two distinct subgroups of proteins. Frontiers in Immunology.
  • 2017. Autoantibody Repertoire in APECED Patients Targets Two Distinct Subgroups of Proteins. Frontiers in Immunology.
  • 2016. Proteome-wide survey of the autoimmune target repertoire in autoimmune polyendocrine syndrome type 1. Scientific Reports.
  • 2016. Epidemiology and health-related quality of life in hypoparathyroidism in Norway. Journal of Clinical Endocrinology and Metabolism. 3045-3053.
  • 2016. Effect of a pre-exercise hydrocortisone dose on short-term physical performance in female patients with primary adrenal failure. European Journal of Endocrinology. 97-105.
  • 2016. Anticommensal responses are associated with regulatory T cell defect in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy patients. Journal of Immunology. 2955-2964.
  • 2016. Analysis of cellular and humoral immune responses against cytomegalovirus in patients with autoimmune Addison's disease. Journal of Translational Medicine.
  • 2016. Abdominal aortic aneurysms - glycaemic status and mortality. Journal of Diabetes and its Complications (JDC). 438-443.
  • 2015. Transglutaminase 4 as a prostate autoantigen in male subfertility. Science Translational Medicine.
  • 2015. The deacetylase Sirt1 is an essential regulator of Aire-mediated induction of central immunological tolerance. Nature Immunology. 737-745.
  • 2015. Peripheral blood cells from patients with autoimmune Addison's disease poorly respond to interferons in vitro, despite elevated serum levels of interferon-inducible chemokines. Journal of Interferon and Cytokine Research. 759-770.
  • 2015. Linkage analysis in autoimmune Addison's disease: NFATC1 as a potential novel susceptibility locus. PLOS ONE.
  • 2015. Interleukin-2 and subunit alpha of its soluble receptor in autoimmune Addison's disease - An association study and expression analysis. Autoimmunity. 100-107.
  • 2015. Hypomagnesemia and functional hypoparathyroidism due to novel mutations in the Mg-channel TRPM6. Endocrine Connections. 215-222.
  • 2015. En mann i 30-årene med diabetes og vitiligo. Tidsskrift for Den norske legeforening. 763-766.
  • 2015. Dominant mutations in the autoimmune regulator AIRE are associated with common organ-specific autoimmune diseases. Immunity. 1185-1196.
  • 2015. Determination of 21-hydroxylase autoantibodies: Inter-laboratory concordance in the Euradrenal International Serum Exchange Program. Clinical Chemistry and Laboratory Medicine. 1761-1770.
  • 2015. Circadian hormone profiles and insulin sensitivity in patients with Addison's disease: a comparison of continuous subcutaneous hydrocortisone infusion with conventional glucocorticoid replacement therapy. Clinical Endocrinology. 28-35.
  • 2015. CTLA-4 as a genetic determinant in autoimmune Addison's disease. Genes and Immunity. 430-436.
  • 2014. The effect of types I and III interferons on adrenocortical cells and its possible implications for autoimmune Addison's disease. Clinical and Experimental Immunology. 351-362.
  • 2014. Functional studies of novel CYP21A2 mutations detected in Norwegian patients with congenital adrenal hyperplasia. Endocrine Connections. 67-74.
  • 2014. Clinical and serologic parallels to APS-I in patients with thymomas and autoantigen transcripts in their tumors. Journal of Immunology. 3880-3890.
  • 2014. CYP21A2 polymorphisms in patients with autoimmune Addison's disease, and linkage disequilibrium to HLA risk alleles. European Journal of Endocrinology. 743-750.
  • 2014. Altered DNA methylation profile in Norwegian patients with Autoimmune Addison's Disease. Molecular Immunology. 208-216.
  • 2013. Screening for X-linked adrenoleukodystrophy among adult men with Addison's disease. Clinical Endocrinology. 316-320.
  • 2013. MHC class II association study in eight breeds of dog with hypoadrenocorticism. Immunogenetics. 291-297.
  • 2013. Induction of CXCL10 chemokine in adrenocortical cells by stimulation through toll-like receptor 3. Molecular and Cellular Endocrinology. 75-83.
  • 2013. BPIFB1 is a lung-specific autoantigen associated with interstitial lung disease. Science Translational Medicine. 10 sider.
  • 2013. Autoantibodies against aromatic amino acid hydroxylases in patients with autoimmune polyendocrine syndrome type 1 target multiple antigenic determinants and reveal regulatory regions crucial for enzymatic activity. Immunobiology. 899-909.
  • 2013. Anti-cytokine autoantibodies suggest pathogenetic links with autoimmune regulator deficiency in humans and mice. Clinical and Experimental Immunology. 263-272.
  • 2013. Anti-cytokine autoantibodies preceding onset of autoimmune polyendocrine syndrome type I features in early childhood. Journal of Clinical Immunology. 1341-1348.
  • 2013. A candidate gene analysis of canine hypoadrenocorticism in 3 dog breeds. Journal of Heredity. 807-820.
  • 2012. Radioligand-binding assay reveals distinct autoantibody preferences for type I interferons in APS I and myasthenia gravis subgroups. Journal of Clinical Immunology. 230-237.
  • 2012. Quality of life in European patients with Addison's Disease: Validity of the disease-specific questionnaire AddiQoL. Journal of Clinical Endocrinology and Metabolism. 568-576.
  • 2012. Genetic, anthropometric and metabolic features of adult Norwegian patients with 21-hydroxylase deficiency. European Journal of Endocrinology. 507-516.
  • 2012. Autoimmune polyendocrine syndrome Type 1: an Eetensive longitudinal study in Sardinian patients. Journal of Clinical Endocrinology and Metabolism. 1114-1124.
  • 2011. TSGA10 – A target for autoantibodies in autoimmune polyendocrine syndrome Type 1 and systemic lupus erythematosus. Scandinavian Journal of Immunology. 147-153.
  • 2011. Multiple loci in the HLA complex are associated with Addison's Disease. Journal of Clinical Endocrinology and Metabolism. E1703-E1708.
  • 2011. Measuring autoantibodies against IL-17F and IL-22 in Autoimmune Polyendocrine Syndrome Type I by radioligand binding assay using fusion proteins. Scandinavian Journal of Immunology. 327-333.
  • 2011. Hypoparathyroidism and autoimmunity in the 22q11.2 deletion syndrome. European Journal of Endocrinology. 345-352.
  • 2011. High frequency of adrenal myelolipomas and testicular adrenal rest tumours in adult Norwegian patients with classical congenital adrenal hyperplasia because of 21-hydroxylase deficiency. Clinical Endocrinology. 753-759.
  • 2011. Grapefruit juice and licorice increase cortisol availability in patients with Addison's disease. European Journal of Endocrinology. 761-769.
  • 2011. Genome-wide copy number variation (CNV) in patients with autoimmune Addison's disease. BMC Medical Genetics. 6 sider.
  • 2011. Cellular immunity and immunopathology in autoimmune Addison’s disease. Molecular and Cellular Endocrinology. 180-190.
  • 2010. Subjective health status in men and women with congenital adrenal hyperplasia: a population-based survey in Norway. European Journal of Endocrinology. 453-459.
  • 2010. Sexuality and Fertility in Women with Addison's Disease. Journal of Clinical Endocrinology and Metabolism. 4354-4360.
  • 2010. Phenotypic Variation in a Large Family with Autosomal Dominant Hypocalcaemia. Hypertension in Pregnancy. 399-405.
  • 2010. Novel sequence variation of AIRE and detection of interferon-ω antibodies in early infancy. Clinical Endocrinology. 641-647.
  • 2010. Flow cytometry study of blood cell subtypes reflects autoimmune and inflammatory processes in autoimmune polyendocrine syndrome type I. Scandinavian Journal of Immunology. 459-467.
  • 2010. Development of a Disease-Specific Quality of Life Questionnaire in Addison's Disease. Journal of Clinical Endocrinology and Metabolism. 545-551.
  • 2010. Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines. Journal of Experimental Medicine. 299-308.
  • 2010. A CLEC16A variant confers risk for juvenile idiopathic arthritis and anti-cyclic citrullinated peptide antibody negative rheumatoid arthritis. Annals of the Rheumatic Diseases. 1471-1474.
  • 2009. X-Linked Congenital Adrenal Hypoplasia with Hypogonadotropic Hypogonadism Caused by an Inversion Disrupting a Conserved Noncoding Element Upstream of the NR0B1 (DAX1) Gene. Journal of Clinical Endocrinology and Metabolism. 4086-4093.
  • 2009. Two adults with adrenal myelolipoma and 21-hydroxylase deficiency. Clinical Medicine : Case Reports. 4 sider.
  • 2009. The purification and application of biologically active recombinant steroid cytochrome P450 21-hydroxylase: The major autoantigen in autoimmune Addison's disease. Journal of Autoimmunity. 58-67.
  • 2009. Tetradecylthioacetic acid attenuates dyslipidaemia in male patients with type 2 diabetes mellitus, possibly by dual PPAR-alpha/delta activation and increased mitochondrial fatty acid oxidation. Diabetes, obesity and metabolism. 304-314.
  • 2009. T Cell Responses to Steroid Cytochrome P450 21-Hydroxylase in Patients with Autoimmune Primary Adrenal Insufficiency. Journal of Clinical Endocrinology and Metabolism. 5117-5124.
  • 2009. Skin changes as diagnostic aid. Tidsskrift for Den norske legeforening. 752-752.
  • 2009. Pulmonary autoimmunity as a feature of autoimmune polyendocrine syndrome type 1 and identification of KCNRG as a bronchial autoantigen. Proceedings of the National Academy of Sciences of the United States of America. 4396-4411.
  • 2009. Programmed death ligand 1 (PD-L1) gene variants contribute to autoimmune Addison's disease and Graves' disease susceptibility. Journal of Clinical Endocrinology and Metabolism. 5139-5145.
  • 2009. Programmed Death Ligand 1 (PD-L1) Gene Variants Contribute to Autoimmune Addison’s Disease and Graves’ Disease Susceptibility. Journal of Clinical Endocrinology and Metabolism. 5139-5145.
  • 2009. Pathogenesis of primary adrenal insufficiency. Baillière's Best Practice & Research. Clinical Endocrinology & Metabolism. 147-157.
  • 2009. Normal overall mortality rate in Addison's disease, but young patients are at risk of premature death. European Journal of Endocrinology. 233-237.
  • 2009. Glucocorticoid replacement therapy and pharmacogenetics in Addison's disease: effects on bone. European Journal of Endocrinology. 993-1002.
  • 2009. Dietary supplementation of tetradecylthioacetic acid increases feed intake but reduces body weight gain and adipose depot sizes in rats fed on high-fat diets. Diabetes, obesity and metabolism. 1034-1049.
  • 2009. Development of a Disease-Specific Quality of Life Questionnaire in Addison’s Disease. Journal of Clinical Endocrinology and Metabolism.
  • 2009. Clinical, Immunological, and Genetic Features of Autoimmune Primary Adrenal Insufficiency: Observations from a Norwegian Registry. Journal of Clinical Endocrinology and Metabolism. 4882-4890.
  • 2009. Clinical manifestations and management of patients with autoimmune polyendocrine syndrome type I. Journal of Internal Medicine. 514-529.
  • 2009. A coding polymorphism in NALP1 confers risk for autoimmune Addison's disease and type 1 diabetes. Genes and Immunity. 120-124.
  • 2009. A CLEC16A variant confers risk for juvenile idiopathic arthritis and anti-CCP negative rheumatoid arthritis. Annals of the Rheumatic Diseases.
  • 2008. Radioimmunoassay for autoantibodies against interferon omega; its use in the diagnosis of autoimmune polyendocrine syndrome type I. Clinical Immunology. 163-169.
  • 2008. Polymorphisms in CLEC16A and CIITA at 16p13 are associated with primary adrenal insufficiency. Journal of Clinical Endocrinology and Metabolism. 3310-3317.
  • 2008. Mutation screening of PTPN22: association of the 1858T-allele with Addison's disease. European Journal of Human Genetics. 977-982.
  • 2008. Microarray analysis reveals down-regulation of the tumour suppressor gene WWOX and up-regulation of the oncogene TYMS in intracranial sporadic meningiomas. Journal of Neuro-Oncology. 251-259.
  • 2008. Interferon autoantibodies associated with AIRE deficiency decrease the expression of IFN-stimulated genes. Blood. 2657-2666.
  • 2008. Autoimmune polyendocrine syndrome type I in Slovakia: relevance of screening patients with autoimmune Addison's disease. European Journal of Endocrinology. 705-709.
  • 2008. Autoimmune polyendocrine syndrome type 1 and NALP5, parathyroid autoantigen. New England Journal of Medicine. 1018-1028.
  • 2008. Autoantibodies against Type I Interferons as an Additional Diagnostic Criterion for Autoimmune Polyendocrine Syndrome Type I. Journal of Clinical Endocrinology and Metabolism. 4389-4397.
  • 2008. AIRE variations in Addison's disease and autoimmune polyendocrine syndromes (APS): partial gene deletions contribute to APS I. Genes and Immunity. 130-136.
  • 2008. A coding polymorphism in NALP1 confers risk for autoimmune Addison's disease and type 1 diabetes. Genes and Immunity.
  • 2007. Pituitary autoantibodies in autoimmune polyendocrine syndrome type 1. Proceedings of the National Academy of Sciences of the United States of America. 949-954.
  • 2007. Fc gamma receptor polymorphisms are not associated with autoimmune Addison's disease. Scandinavian Journal of Immunology. 555-558.
  • 2007. Epitope mapping of human aromatic L-amino acid decarboxylase. Biochemical and Biophysical Research Communications - BBRC. 692-698.
  • 2007. Continuous subcutaneous hydrocortisone infusion in Addison's disease. European Journal of Endocrinology. 109-112.
  • 2007. Clinical evolution of Kearns-Sayre syndrome with polyendocrinopathy and respiratory failure. Acta Neurologica Scandinavica. 64-67.
  • 2007. Autoimmune polyendocrine syndrome type 1 in Norway: Phenotypic variation, autoantibodies, and novel mutations in the autoimmune regulator gene. Journal of Clinical Endocrinology and Metabolism. 595-603.
  • 2006. The substrate-binding domain of 21-hydroxylase, the main autoantigen in autoimmune Addison's disease, is an immunodominant T cell epitope. Endocrinology. 2411-2416.
  • 2006. Saliva cortisol measurement: simple and reliable assessment of the glucocorticoid replacement therapy in Addison's disease. Journal of Endocrinological Investigation. 727-731.
  • 2006. Detection of autoantibodies to the BTB-kelch protein KLHL7 in cancer sera. Scandinavian Journal of Immunology. 325-335.
  • 2006. Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1. PLoS Medicine. 1152-1164.
  • 2005. Primær binyrebarksvikt - årsaker, diagnostikk og behandling (=Primary adrenal failure - Causes, diagnostics and therapy). Tidsskrift for Den norske legeforening. 155-158.
  • 2005. Primær binyrebarksvikt - årsaker, diagnostikk og behandling. Tidsskrift for Den norske legeforening. 155-158.
  • 2005. CTLA4 polymorphisms are associated with vitiligo, in patients with concomitant autoimmune diseases. Pigment Cell Research. 55-58.
  • 2005. CTLA4 polymorphisms are associated with vitiligo, in patients with concomitant autoimmune diseases. Pigment Cell Research.
  • 2005. Autoantibodies to a NR2A peptide of the glutamate/NMDA receptor in sera of patients with systemic lupus erythematosus. Annals of the Rheumatic Diseases. 210-213.
  • 2004. Pyridoxal phosphatase is a novel cancer autoantigen in the central nervous system. British Journal of Cancer. 1508-1514.
  • 2004. Prevalence and clinical associations of 10 defined autoantibodies in autoimmune polyendocrine syndrome type I. Journal of Clinical Endocrinology and Metabolism. 544-547.
  • 2004. Polymorphisms in the cytotoxic T lymphocyte antigen-4 gene region confer susceptibility to Addison's disease. Journal of Clinical Endocrinology and Metabolism. 3474-3476.
  • 2004. Paraneoplastic antibodies against HuD detected by a sensitive radiobinding assay. Journal of Neurology. 197-203.
  • 2004. Chronic mucocutaneous candidiasis and primary hypothyroidism in two families. European Journal of Pediatrics. 604-611.
  • 2004. Chronic mucocutaneous candidiasis and primary hypothyroidism in two families. European Journal of Pediatrics. 604-611.
  • 2004. Autoantibodies against 21-hydroxylase and side-chain cleavage enzyme in autoimmune Addison's disease are mainly immunoglobulin G1. European Journal of Endocrinology. 49-56.
  • 2004. Analysis of antibody reactivity against cysteine sulfinic acid decarboxylase, a pyridoxal phosphate-dependent enzyme, in endocrine autoimmune disease. Journal of Clinical Endocrinology and Metabolism. 1636-1640.
  • 2003. Replacement therapy in Addison's disease. Expert Opinion on Pharmacotherapy. 2145-2149.
  • 2003. Replacement of Dehydroepiandrosterone in Adrenal Failure: No Benefit for Subjective Healt Status and Sexuality in a 9-Month, Randomized, Parallel Group Clinical Trial. Journal of Clinical Endocrinology and Metabolism. 1112-1118.
  • 2003. Histidine decarboxylase, a pyridoxal phosphate-dependent enzyme, is an autoantigen of gastric enterochromaffin-like cells. Journal of Clinical Endocrinology and Metabolism. 1445-1452.
  • 2003. High frequency of coeliac disease among patients with autoimmune adrenocortical failure. Scandinavian Journal of Gastroenterology. 511-515.
  • 2003. Døgnrytme til besvær. Tidsskrift for Den norske legeforening. 1858-1859.
  • 2002. Subjective health status in Norwegian patients with Addison's disease. Clinical Endocrinology. 581-588.
  • 2002. Predictors of outcome and comparison of different drug regimens for the prevention of relapse in patients with Graves' disease. European Journal of Endocrinology. 583-589.
  • 2002. Mutational analysis of the autoimmune regulator gene in sporadic autoimmune Addison`s disease can reveal patients with unidentified autoimmune polyendocrine syndrome type I. European Journal of Endocrinology. 519-522.
  • 2002. High prevalence and increasing incidence of Addison's disease in western Norway. Clinical Endocrinology. 787-791.
  • 2002. Endoscopic ultrasonography for preoperative diagnosis and localization of insulinomas. Scandinavian Journal of Gastroenterology. 732-737.
  • 2002. Autoimmune adrenocortical failure in Norway. Autoantibodies and HLA class II associations related to clinical features. Journal of Clinical Endocrinology and Metabolism. 618-623.
  • 2002. Autoimmune Regulator and Human Leucocyte Antigen Genotypes as Determinants of the Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy Phenotype. Journal of Clinical Endocrinology and Metabolism. 2568-2574.
  • 2001. The transcription factors SOX9 and SOX10 are vitiligo autoantigens in autoimmune polyendocrine syndrome type I. Journal of Biological Chemistry. 35390-35395.
  • 2001. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. American Journal of Human Genetics. 49-54.
  • 2001. Autoimmune polyendocrine syndrome type 1 (APS I) in Norway. Clinical Endocrinology. 211-217.
  • 2001. Acute adrenal insufficiency--symptoms and treatment. Tidsskrift for Den norske legeforening. 1260.
  • 2000. Pteridine-dependent hydroxylases as autoantigens in autoimmune polyendocrine syndrome type 1. Journal of Clinical Endocrinology and Metabolism. 2944-2950.
  • 2000. Pteridin dependent hydroxylases as autoantigens in autoimmune polyendocrine syndrome type 1. Journal of Clinical Endocrinology and Metabolism. 2944-2950.
  • 2000. Oral dehydroepiandrosterone (DHEA) replacement therapy in women with Addison's disease. Clinical Endocrinology. 775-780.
  • 2000. Oral dehydroepiandrosterone (DHEA) replacement therapy in women with Addison's disease. Clinical Endocrinology. 775-780.
  • 2000. Inhibition of aromatic L-amino acid decarboxylase activity by human autoantibodies. Clinical and Experimental Immunology. 420-423.
  • 2000. Inhibition of aromatic 1-amino acid decarboxylase by human autoantibodies. Clinical and Experimental Immunology. 420-423.
  • 2000. Identification of tyrosine hydroxylase as an autoantigen in autoimmune polyendocrine syndrome type I. Biochemical and Biophysical Research Communications - BBRC. 456-461.
  • 2000. Identification of tyrosine hydroxylase as an autoantigen in autoimmune polyendocrine syndrome type I. Biochemical and Biophysical Research Communications - BBRC. 456-461.
  • 2000. Autoantibodies against aromatic L-amino acid decarboxylase delineate a subgroup of patients with Addison's disease. Journal of Clinical Endocrinology and Metabolism. 460-463.
  • 2000. Autoantibodies against aromatic L-amino acid decarboxylase delineate a subgroup of patients with Addison's disease. Journal of Clinical Endocrinology and Metabolism. 460-463.
  • 1999. Antibodies Against Hair Follicles are Associated with Alopecia Totalis in Autoimmune Polyendocrine Syndrome Type I. Journal of Investigative Dermatology. 1054-1058.
  • 1998. Three sisters with Addison's disease. Journal of Clinical Endocrinology and Metabolism. 4204-4206.
  • 1998. Primær binyrebarksvikt - en diagnostisk utfordring. Tidsskrift for Den norske legeforening. 542-544.
  • 1998. Identification of tryptophan hydroxylase as an intestinal autoantigen. The Lancet. 279-283.
  • 1998. Identification of tryptophan hydroxylase as an intestinal autoantigen. The Lancet. 279-283.
  • 1998. A family with hereditary extra-adrenal paragangliomas without evidence for mutations in the Von Hippel Lindau disease or ret genes. Clinical Endocrinology. 11-16.
  • 1998. A cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphism is associated with autoimmune Addison's disease in English patients. Clinical Endocrinology. 609-614.
  • 1997. Cytochrome P450IA2 and aromatic L-amino acid decarboxylase are hepatic autoantigens in autoimmune polyendocrine syndrome type I. FEBS Letters. 439-445.
  • 1997. Chromogranin A and chromogranin B in phaeochromocytoma. European Journal of Endocrinology. 67-73.
  • 1997. Autoantibodies against aromatic L-amino acid decarboxylase in autoimmune polyendocrine syndrome type I correlate with the presence of autoimmune hepatitis and vitiligo. Journal of Clinical Endocrinology and Metabolism. 147-150.
Vitenskapelig foredrag
  • 2005. Variable expression of FKBP51 in Addison's Disease - a parameter of glucocorticoid sensitivity ?
  • 2005. Severe neurological impairment in patient with allgrove syndrome caused by frame shift mutation G363X (1066-1067delCT) and novel missense mutation W272S (TGG->TCG).
  • 2005. Ganglioneuroma in patient with adrenal insufficiency - rare coincidence of adrenal cortex and medulla disorders.
  • 2005. Cellular immunity to 21-hydroxylase in patients with autoimmune Addison's disease.
  • 2003. Meet the expert session on "Hypoadrenalism: substitution by corticoids and androgens".
  • 2003. Autoimmune polyendocrine syndromes.
  • 2003. Autoimmune Addisons disease and polyendocrine syndromes.
  • 2002. Prevalens og insidens av Addison's sykdom i Vest-Norge Livskvalitet hos pasienter med Addison's sykdom.
  • 2002. Pituitary tumours in multiple endocrine neoplasia type 1.
  • 2002. Høy forekomst av cøliaci hos pasienter med autoimmun binyrebarksvikt.
  • 2002. Dehydroepiandrosterone replacement in adrenal failure.
  • 2002. Autoimmune polyendocrine syndromes.
  • 2001. Klinisk handläggning av APS I patienter.
  • 2001. Autoimmun primær binyrebarksvikt i Norge. Autoantistoffer og HLA klasse II assosiasjoner relatert til kliniske manifestasjoner.
  • 1997. Ductal autoantigens in Sjøgren's syndrome.
Sammendrag/abstract
  • 2013. Human leukocyte antigen (DQ2/DQ8) and 21-hydroxylase antibodies determine the thyroid peroxidase antibody status of patients in autoimmune Addison's disease. Experimental and clinical endocrinology & diabetes. 2 sider.
  • 2013. Dominant Inheritance in Autoimmune Endocrine Syndrome Type 1. Scandinavian Journal of Immunology. 306-307.
  • 2013. Characterisation of the CYP21A2 Gene in Patients with Autoimmune Addison's Disease. Scandinavian Journal of Immunology. 310-310.
  • 2012. Poly (I:C)-induced CXCL10 production in adrenocortical cells - implications for autoimmune Addison's disease? Immunology. 300-301.
  • 2012. Mice deficient for the autoimmune regulator, Aire, display altered T cell responses against 21-hydroxylase, the major autoantigen in autoimmune Addison's disease. Immunology. 542-542.
  • 2012. Measuring autoantibodies against IL-17F and IL-22 in autoimmune polyedocrine sydnrome type I. Immunology. 673-674.
  • 2012. Deviant expression of defensins in sera and saliva of patients with autoimmune polyendocrine syndrome type I. Immunology. 211-212.
  • 2011. Oral manifestations of autoimmune polyendocrine syndrome type I. Caries Research. 186-187.
  • 2011. Endogenous Production of CXC Chemokine Ligand 10 (CXCL10) by Adrenocortical Cells and its Implications for Autoimmune Addison's Disease. Scandinavian Journal of Immunology. 371-371.
  • 2011. Cytokine Antibodies in Autoimmune Polyendocrine Syndrome Type I Correlates to Chronic candidiasis. Scandinavian Journal of Immunology. 379-379.
  • 2010. The Possible Roles of Interferon-Gamma, CXC Chemokine Ligand 10 (CXCL10) and the CXCR3 Circuit in the Pathogenesis of Autoimmune Addison's Disease. Scandinavian Journal of Immunology. 479-480.
  • 2010. Sexuality, Fertility and Androgens in Women with Addison's Disease. Endocrine reviews. 3.
  • 2010. Nucleoporin 62, a Novel Autoantigen in Patients with Autoimmune Polyendocrine Syndrome Type I (APS I). Scandinavian Journal of Immunology. 493-494.
  • 2010. Immunoreactivity against kidney collecting ducts in patients with autoimmune polyendocrine syndrome type 1 and systemic hypertension. Endocrine journal. S641-S641.
  • 2010. Grapefruit and Liquorice Increase Bioavailable Cortisol in Addison's Disease. Endocrine reviews. 1 sider.
  • 2009. Loss of AIRE Expression in Thymoma Tissue Associated with Multiple Endocrine Autoimmunity: A Novel Case of APS1. Clinical Immunology. S128-S128.
  • 2008. 21-hydroxylase as a T cell autoantigen in autoimmune Addison's disease. Scandinavian Journal of Immunology. 191-191.
  • 2007. Epitope mapping of human aromatic L-amino acid decarboxylase. Scandinavian Journal of Immunology. 592-592.
Vitenskapelig oversiktsartikkel/review
  • 2018. Autoimmune polyendocrine syndromes. 1132-1141.
  • 2016. Management of endocrine disease - Epidemiology, quality of life and complications of primary adrenal insufficiency: A review. R107-R116.
  • 2016. Autoimmune regulator and self-tolerance - molecular and clinical aspects. 127-140.
  • 2016. AIRE-mutations and autoimmune disease. 8-15.
  • 2010. Autoimmune polyendocrine syndromes: clues to type 1 diabetes pathogenesis. 479-487.
  • 2009. Immunology of Addison's Disease and premature ovarian failure. 389-405.
  • 2009. Autoantibodies in autoimmune polyglandular syndrome type I patients react with major brain neurotransmitter systems. 1-20.
  • 2008. Replacement therapy for Addison's disease: recent developments. 497-509.

Se fullstendig oversikt over publikasjoner i CRIStin.

Ten papers of special significance

1. Ueland GÅ, Methlie P, Jøssang DE, Sagen JV, Viste K, Thordarson HB, Heie A, Grytaas M, Løvås K, Biermann M, Husebye ES. Adrenal Venous Sampling for Assessment of Autonomous Cortisol Secretion. J Clin Endocrinol Metab. 2018 Dec 1;103(12):4553-4560. First major study showing the importance of adrenal venous sampling in the evaluation of adrenal Cushing’s syndrome.

2. Ueland GÅ, Methlie P, Øksnes M, Thordarson HB, Sagen J, Kellmann R, Mellgren G, Ræder M, Dahlqvist P, Dahl SR, Thorsby PM, Løvås K, Husebye ES. The short cosyntropintest revisited - new normal reference range using LCMSMS. J Clin Endocrinol Metab. 2018 Feb 14. doi: 10.1210/jc.2017-02602. [Epub ahead of print]. First major re-evaluation of the short synacthen test using LCMSMS.

3. Husebye ES, Anderson MS, Kämpe O. Autoimmune polyendocrine syndromes. New Engl.J Med, 378, 1132-41, 2018 (IF 72.4). Invited review that summarizes the current status on polyendocrine syndromes.

4. Orlova EM, Sozaeva LS, Kareva MA, Oftedal BE, Wolff ASB, Breivik L, Zakharova EY, Ivanova ON, Kämpe O, Dedov II, Knappskog PM, Peterkova VA, and Husebye ES. Expanding the phenotypic and genotypic landscape of autoimmune polyendocrine syndrome type-1. J Clin Endocrinol Metabol 102, 3546-56, 2017 (IF 5.5). Clinical and immunological characterization of the hitherto largest cohort of patients with autoimmune polyendocrine syndrome type 1 in the world.

5. Landegren N, Sharon D, Shum AK, Khan IS, Fasano K, Hallgren Å, Kampf C, Freyhult E, Ardesjö-Lundgren B, Alimohammadi M, Rathsman S, Ludvigsson JF, Hedelin H, Lundh D, Motrich R, Rivero V, Fong L, Giwercman A, Gustafsson J, Perheentupa J, Husebye ES, Anderson MS, Snyder M, Kämpe O. Prostatic transglutaminase 4 as a male-specific autoantigen. Science Trans Med 2015 7(292):292ra101. (IF 16.8). Identification of transglutaminase 4 as the first geneder-specific autoantigen assosiated with autoimmune prostatitis. Transglutaminase 4 is an autoantigen in both humans and in autoimmune regulator knockout mice. Furthermore it was demonstrated that transglutaminase 4 belows to the family of aire-regulated genes.

6. Chuprin C, Avin A, Goldfarb Y, Herzig Y, Levi B, Jacob A, Sela A, Katz S1, Grossman M, Guyon C, Rathaus M, Cohen H, Sagi I, Giraud M, McBurney M, Husebye ES, Abramson J. Sirt1 is essential for Aire-mediated induction of central immunological tolerance. Sirt1 is an essential regulator of Aire-mediated induction of central immunological tolerance. Nature Immunology 16,737-45, 2015, (IF 21.5). Demonstration of Sirtuin-1 as a key regulator of AIRE by deacetylation using mouse models. Sirt1-mutations have been described in monogenic autoimmune diabetes mellitus type 1

7. Oftedal BE, Hellesen A, Erichsen MM, Bratland B, Vardi A, Perheentupa J, Kemp EH, Fiskerstrand T, Viken MK, Weetman AP, Fleishman SJ, Banka S, Newman WG, Sewell WAC, Sozaeva LG, Zayats T, Haugarvoll K, Orlova EM, Haavik J Johansson S, Knappskog PM, Løvås L, Wolff ASB, Abramson J, Husebye ES. Dominant Autoimmune Regulator mutations associated with common organ-specific autoimmune diseases. Immunity 42,1185-96, 2015. (IF 22.8). Identification of a new mechanism for familial autoimmunity by identification of several dominant negative mutations in the autoimmune regulator gene. The study includes clinical and immunological characterization of patients as well as functional studies of the mutants demonstrating the dominant negative effect. The paper was accompanied by an editorial and front page cover illustration (June issue).

8. Dawoodji A, Chen JL, Shepherd D, Dalin F, Tarlton A, Alimohammadi M, Penna-Martinez M, Meyer G, Mitchell AL, Gan EH, Bratland E, Bensing S, Husebye ES, Pearce SH, Badenhoop K, Kämpe O, Cerundolo V. High Frequency of Cytolytic 21-Hydroxylase-Specific CD8+ T Cells in Autoimmune Addison's Disease Patients. J Immunol 193, 2118-26, 2014 (IF 4.8). Demonstration of both CD8 and CD4 T cell reativity against 21-hydroxylase and identification of distinct epitopes, building on previous observation by us Bratland et al JCEM, 2009 and Husebye et al, Endocrinology, 2005.

9. Mitchell AL, Macarthur KD, Gan EH, Baggott LE, Wolff AS, Skinningsrud B, Platt H, Short A, Lobell A, Kämpe O, Bensing S, Betterle C, Kasperlik-Zaluska A, Zurawek M, Fichna M, Kockum I, Nordling Eriksson G, Ekwall O, Wahlberg J, Dahlqvist P, Hulting AL, Penna-Martinez M, Meyer G, Kahles H, Badenhoop K, Hahner S, Quinkler M, Falorni A, Phipps-Green A, Merriman TR, Ollier W, Cordell HJ, Undlien D, Czarnocka B, Husebye ES, Pearce SH. Association of autoimmune Addison's disease with alleles of STAT4 and GATA3 in European cohorts. Plos One, 9(3):e88991. doi: 10.1371/journal.pone.0088991. eCollection 2014. (IF 3.5). Results of a FP7-Euradrenal (coordinator Husebye) to find novel disease associations in autoimmune Addison’s disease involving Addison cohorts from 6 European countries totalling over 2000 patients with autoimmune Addison’s disease. Several novel associations were found including GATA3 and STAT4

10. Oksnes M, Björnsdottir S, Isaksson M, Methlie P, Carlsen S, Nilsen RM, Broman JE, Triebner K, Kämpe O, Hulting AL, Bensing S, Husebye ES, Løvås K. Continuous Subcutaneous Hydrocortisone Infusion versus Oral Hydrocortisone Replacement for Treatment of Addison's Disease: A Randomized Clinical Trial. J Clin Endocrinol Metabol 99,1665-74, 2014. (IF 5.5). Clinical study of circadian cortisol treatment first introduced by us. Using subcutaneous cintinous infusion of cortisol by an insulin pump we were able to restore circadian levels of cortisol. The preatment was safe and patients reported improved quality of life.

Spesialist i endokrinologi og indremedisin

Leder K.G. Jebsen-senter for autoimmune sykdommer

Koordinator av H2020 Ultradian